[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615677":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":27,"interventions":40,"overallOfficials":48,"centralContacts":52,"locations":60,"responsibleParty":74,"collaborators":11,"id":76,"slug":11,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":11,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Frequency of Adverse Events (AEs)",null,"Up to Week 24",[14],{"measure":15,"description":11,"timeFrame":16},"Concentration of ALN-4285 in Plasma","Up to Day 3",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":23},"TRIPLE",[24,25,26],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[28,34],{"label":29,"type":30,"description":31,"interventionNames":32},"ALN-4285","EXPERIMENTAL","Participants will be administered ALN-4285 subcutaneously (SC)",[33],"Drug: ALN-4285",{"label":35,"type":36,"description":37,"interventionNames":38},"Placebo","PLACEBO_COMPARATOR","Participants will be administered placebo SC",[39],"Drug: Placebo",[41,45],{"type":42,"name":29,"description":43,"armGroupLabels":44,"otherNames":11},"DRUG","ALN-4285 will be administered SC",[29],{"type":42,"name":35,"description":46,"armGroupLabels":47,"otherNames":11},"Placebo will be administered SC",[35],[49],{"name":50,"affiliation":5,"role":51},"Medical Director","STUDY_DIRECTOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":11,"email":57},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":54,"role":55,"phone":59,"phoneExt":11,"email":57},"1-877-256-9526",[61],{"facility":62,"status":63,"city":64,"state":11,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":11},"Clinical Trial Site","RECRUITING","London","NW10 7EW","United Kingdom","UK",{"type":69,"coordinates":70},"Point",[71,72],-0.12574,51.50853,{"lat":72,"lon":71},{"type":75,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100615677",false,"NCT07295717","A Study to Evaluate ALN-4285 in Adult Healthy Volunteers","A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Has a body mass index (BMI) of ≥18.0 kg\u002Fm\\^2 and ≤30 kg\u002Fm\\^2\n* Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator\n\nExclusion Criteria:\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>upper limit of normal (ULN)\n* Has total bilirubin \\>ULN\n* Has systolic blood pressure \\>140 mmHg and\u002For a diastolic blood pressure \\>90 mmHg\n* Has an estimated glomerular filtration (eGFR) of \\\u003C90 mL\u002Fmin\u002F1.73m\\^2 at screening\n* Has received an investigational agent within the last 30 days or 5 half-lives",true,"ALL","18 Years","65 Years",{"count":87,"type":88},76,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","The purpose of this study is to:\n\n* evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers\n* characterize the single-dose pharmacokinetics (PK) of ALN-4285",[94],"Healthy Volunteers",[96,97],"siRNA","RNAi therapeutics","2026-06-10",{"date":100,"type":101},"2026-06-12","ACTUAL",{"date":103,"type":101},"2025-12-12",{"date":105,"type":88},"2027-03-23",{"name":5,"class":6},1]